ADVISORY, Dec. 18, 2013 (GLOBE NEWSWIRE) --
What:
TetraLogic Pharmaceuticals Corporation [TLOG], a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics called SMAC-mimetics for the treatment of cancers and viral diseases, will visit the NASDAQ MarketSite in Times Square in celebration of its recent initial public offering (IPO) which occurred on Thursday, December 12, 2013.
In honor of the occasion, J. Kevin Buchi, TetraLogic's President and Chief Executive Officer, will ring the Opening Bell.
Where:
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Thursday, December 19, 2013 – 9:15 a.m. to 9:30 a.m. ET
Contact:
Pete A. Meyers
Chief Financial Officer
(610) 889-9900, x103
Pete.Meyers@tetralogicpharma.com
NASDAQ MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaqomx.com
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx.
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About TetraLogic Pharmaceuticals Corporation [TLOG]:
TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases, or SMAC-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body's immune system to self-destruct. Birinapant, our clinical-stage product candidate, is currently being tested in Phase 1 and Phase 2 oncology clinical trials for hematological malignancies and multiple solid tumors.
About NASDAQ OMX Group:
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 80 marketplaces in 50 countries, and approximately 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,300 listed companies with a market value of over $7 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.
-NDAQA-
